Roxanne Brown
Adult Health · Baltimore, MDNPI 1518741537
Payments from drug & device makers
Across 89 payments — averaging $19.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$412
- Lilly USA, LLC$270
- AstraZeneca$217
- Johnson & Johnson$213
- Pfizer$206
- AbbVie$80
- plus $342 from 12 others
What the payments were for
- Food & beverage$1,741100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $412 |
| Lilly USA, LLC | 16 | $270 |
| AstraZeneca | 11 | $217 |
| Johnson & Johnson | 9 | $213 |
| Pfizer | 9 | $206 |
| AbbVie | 3 | $80 |
| Madrigal Pharmaceuticals | 2 | $57 |
| Amgen | 2 | $45 |
| Merck | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Boston Scientific | 1 | $26 |
| Ardelyx, Inc. | 1 | $24 |
| Dexcom, Inc. | 1 | $22 |
| Exact Sciences | 1 | $20 |
| Medtronic | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Bayer | 1 | $16 |
How this compares
$1,741 in reported general payments places this provider in the 75th percentile of 542 adult health providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 13 | $17,325 |
| Candesartan Cilexetil | 12 | $1,265 |
| Gabapentin | 30 | $818 |
| Atorvastatin Calcium | 34 | $688 |
| Rosuvastatin Calcium | 26 | $566 |
| Amlodipine Besylate | 61 | $540 |
| Zolpidem Tartrate ErZolpidem Tartrate | 12 | $526 |
| Pantoprazole Sodium | 15 | $448 |
| Lisinopril | 39 | $437 |
| Pravastatin Sodium | 12 | $402 |
| Escitalopram Oxalate | 12 | $371 |
| Metoprolol Succinate | 18 | $328 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $292 |
| Losartan Potassium | 19 | $290 |
| Alprazolam | 21 | $220 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $217 | $17,32513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 542 adult health providers in Maryland.
Other adult health in Baltimore
- Christopher RobersonBaltimore$180K
- Amit DhirBaltimore$97K
- Angie PriceBaltimore$96K
- Brendon BowerBaltimore$64K
- Caitlin NassBaltimore$46K
- Sarah RileyBaltimore$24K
- Monica LovinsBaltimore$18K
- Elizabeth ChandlerBaltimore$17K
- Clifton DawsonBaltimore$14K
- Selina YeasminBaltimore$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.